Researchers Seek Ways to Minimize Off-Target Effects
Literature Review: Dials for Cas9
Methods to Control Cas9-Based Technologies Across Numerous Dimensions Is Still Lacking
Opening Up Relieves Downstream Bottlenecks
Celebrate the Downstream Improvements That Have Been Achieved, Even If They Fail to Match Upstream Improvements
Top 10 European Biopharma Clusters
The Continent’s Key Academic and Industrial Centers for Drug Development
GEN Reports on Global Bioclusters Vying for Life Science Dominance
New Rochelle, NY, June 5, 2012— “The U.S. remains the world’s major superpower but its dominance in biopharma is slipping,” reports Genetic Engineering & Biotechnology News (GEN). China and India are the main challengers as they add innovative capabilities to their rapidly expanding biotechnology industries, according to the most recent issue of GEN.
“Both China and India have targeted bioscience as a key economic sector for the 21st century,” said John Sterling, Editor-in-Chief of GEN. “They are providing strong political and financial support to create dominant bioindustries.”
The GEN article specifically compares the current status of biotech in China and India to that of two significant U.S. regions, California and Massachusetts, two states that have long served as anchors for the country’s biotechnology efforts. Biotechnology in India and China is growing faster than in the U.S. and other countries. Both Eastern nations emerged more than a decade ago as offshoring havens driven by lower wages and less red tape.
India has capitalized on strong chemistry, generic drug development, and working as a service sector. China invested heavily in biopharma infrastructure and its drug market zoomed from $33 billion in 2007 to $126 billion in the first seven months of 2011.
The China/India article also features GEN’s picks for the top 15 U.S. biotech clusters and the top 10 Non-U.S. bioclusters.
Supplementing the China/India analysis are articles on U.K. Biopharma Bouncing Back, Emerging Markets Turning to Innovation, and Intellectual Property Considerations for Firms Doing Business in China and India.